Effect of ferric ions on reactive oxygen species formation, cervical cancer cell lines growth and E6/E7 oncogene expression

Toxicology in Vitro

Volumn 25, Issue 1, 2011, Pages 160-166

  Poljak Blazi, Marija ^a   Jaganjac, Morana ^a   Sabol, Ivan ^a   Mihaljevic, Branka ^a   Matovina, Mihaela ^a   Grce, Magdalena ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

A431; E6 E7 oncogene expression; Ferric sorbitol citric acid complex; HeLa; Human papilloma viruses; SiHa

Indexed keywords

FERRIC ION; IRON SORBITEX; PROTEIN E6; PROTEIN E7; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN A431; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; ONCOGENE; SIHA CELL; TUMOR CELLS AND CELL LINES; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CITRATES; CULTURE MEDIA, CONDITIONED; FEMALE; FERRIC COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; OSMOLAR CONCENTRATION; PAPILLOMAVIRUS E7 PROTEINS; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; RNA, MESSENGER; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 78650518803     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.10.013     Document Type: Article

References (47)

1. Becton D.L., Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988, 48:7189-7192.
2. Berridge M.V., Tan A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 1993, 303:474-482.
3. Boelaert J.R., Weinberg G.A., Weinberg E.D. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect. Agents Dis. 1996, 5:36-46.
4. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papilloma virus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 1995, 87:796-802.
5. Brodie C., Siriwardana G., Lucas J., Schleicher R., Terada N., Szepesi A., Gelfand E., Seligman P. Neuroblastoma sensitivity to growth inhibition by desferrioxamine. Evidence for a block in G1 phase of the cell cycle. Cancer Res. 1993, 53:3968-3975.
6. Cipak A., Jaganjac M., Tehlivets O., Kohlwein S.D., Zarkovic N. Adaptation to oxidative stress induced by polyunsaturated fatty acids in yeast. Biochim. Biophys. Acta 2008, 1781:283-287.
7. Davies K.J. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999, 48:41-47.
8. Drakesmith H., Prentice A. Viral infection and iron metabolism. Nat. Rev. Microbiol. 2008, 6:541-552.
9. Eichberger T., Regl G., Ikram M.S., Neill G.W., Philpott M.P., Aberger F., Frischauf A.M. FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma. J. Invest. Dermatol. 2004, 122:1180-1187.
10. Finzer P., Aguilar-Lemarroy A., Rösl F. The role of human papilloma virus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 2002, 188:15-24.
11. Flajsig I., Poljak-Blazi M. Influence of iron on proliferation and cell cycle kinetics on cultured malignant and non-malignant cell. Oncology 1990, 47:443-446.
12. Fukuchi K., Tomoyasu S., Tsuruoka N., Gomi K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett. 1994, 350:139-142.
13. Gackowski D., Kruszewsk M., Banaszkiewicz Z., Jawien A., Olinski R. Lymphocyte labile iron pool, plasma iron, transferrin saturation and ferritin levels in colon cancer patients. Acta Biochim. Pol. 2002, 49:269-272.
14. Georgiou N.A., Van der Bruggen T., Oudshoorn M., Nottet H.S.M.L., Marx J.J.M., Van Asbeck B.S. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone and bleomycin. J. Infect. Dis. 2000, 181:484-490.
15. scavenger in aqueous solutions and in biological systems. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1984, 46:725-729.
16. Goncalves T.L., Erthal F., Corte C.L.D., Müller L.G., Piovezan C.M., Noguera C.W., Rocha J.B.T. Involvement of oxidative stress in the pre-malignant and malignant states of cervical cancer in women. Clin. Biochem. 2005, 38:1071-1075.
17. Gropper S.S., Kerr S., Barksdale J.M. Non-anaemic iron deficiency, oral iron supplementation, and oxidative damage in college-aged females. J. Nutr. Biochem. 2003, 14:409-415.
18. Hagar H., Ueda N., Shah S.V. Role of reactive oxygen metabolites in DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells. Am. J. Physiol. 1996, 271:F209-F215.
19. Hann H.W.L., Stahlhut M.W., Hann C.L. Effect of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 1990, 11:566-569.
20. Haq R.U., Werely J.P., Chitambar C.R. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp. Hematol. 1995, 23:428-432.
21. IARC, 2007. Monographs on the evaluation of carcinogenic risks to humans, vol. 90. Human Papillomaviruses. IARC, WHO Press, Lyon.
22. Jaganjac M., Poljak-Blazi M., Zarkovic K., Schaur R.J., Zarkovic N. The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma. Cancer Lett. 2008, 260:180-186.
23. Jaganjac M., Matijevic T., Cindric M., Cipak A., Mrakovcic L., Gubisch W., Zarkovic N. Induction of CMV-1 promoter by 4-hydroxy-2-nonenal in human embryonic kidney cells. Acta Biochim. Pol. 2010, 57:179-183.
24. Lee J.E., Kim C.Y., Giaccia A.J., Giffard R.G. The E6 and E7 genes of human papilloma virus-type 16 protect primary astrocyte cultures from injury. Brain Res. 1998, 795:10-16.
25. Looker A.C., Dallman P.R., Carrol M.D., Gunter E.W., Johnson C.L. Prevalence of iron deficiency in the United States. JAMA 1997, 277:973-976.
26. Meissner J.D. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J. Gen. Virol. 1999, 80:1725-1733.
27. Nishimura A., Nakahara T., Ueno T., Sasaki K., Yoshida S., Kyo S., Howley P.M., Sakai H. Requirement of E7 oncoprotein for viability of HeLa cells. Micro. Infect. 2006, 8:984-993.
28. Nurtjahja-Tjendraputra E., Fu D., Phang J.M., Richardson D.R. Iron chelation regulates cyclin D1 expression via the proteosom: a link to iron deficiency-mediated growth suppression. Blood 2007, 109:4045-4054.
29. Poljak-Blazi M., Jaganjac M., Mustapic M., Pivac N., Muck-Seler D. Acute immunomodulatory effects of iron polyisomaltosate in rats. Immunobiology 2009, 214:121-128.
30. Poljak-Blazi M., Stancic-Rokotov D., Ferle-Vidovic A. Inhibitory effect of iron on melanoma B16 growth. Period. Biol. 1985, 87:17-21.
31. Poljak-Blazi M., Zarkovic N., Schaur R.J. Impaired proliferation and DNA synthesis of a human tumour cell line (HeLa) caused by short treatment with ant anaemic drug Jectofer (ferric-sorbitol-citrate) and the lipid peroxidation product 4-hydroxynonenal. Canc. Biother. Radiopharm. 1998, 13:395-402.
32. Poljak-Blazi M., Kralj M., Hadzija P.M., Zarkovic N., Zarkovic K., Waeg G. Involvement of lipid peroxidation, oncogene expression and induction of apoptosis in the anti-timorous activity of ferric-sorbitol-citrate. Cancer. Biother. Radiopharm. 2000, 15:285-293.
33. Powell L.W., Jazwinska E., Halliday J.W. Primary iron overload. Iron Metabolism in Health and Disease 1994, 227-270. London, Saunders. J.H. Brock, J.W. Halliday, M.J. Pippard, L.W. Powell (Eds.).
34. Prutki M., Poljak-Blazi M., Mihaljevic B., Orescanin V., Zarkovic N. Uptake of anti-anaemic substance ferric-sorbitol-citrate by normal and malignant cells and its effects on expression of TfR1 and feritin. Cancer. Biother. Radiopharm. 2006, 21:638-646.
35. Richardson D., Ponka P., Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and tranferrin uptake by the human malignant melanoma cell. Cancer Res. 1994, 54:685-689.
36. Rosenkranz A.R., Schmaldienst S., Stuhlmeier K.M., Chen W., Knapp W., Zlabinger G.J. A microplate assay for the detection of oxidative products using 2,7-dichlorofluorescin-diacetate. J. Immunol. Methods 1992, 156:39-45.
37. Schumann K. Safety aspects of iron in food. Ann. Nutr. Metab. 2001, 45:91-101.
38. Shah K.V., Howley P.M. Papillomaviruses. Fields Virology 1996, 2077-2109. Lippincott-Raven Press, Philadelphia, PA. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
39. Simonart T., Boelaert J.R., Mosselmans R., Andrei G., Noel J., De Clercq E., Snoeck R. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol. Oncol. 2002, 85:95-102.
40. Simonart T., Degraef C., Andrei G., Mosselmans R., Hermans P., Van Vooren J.P., Noel J.C., Boelaert J.R., Snoeck R., Heenen M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J. Invest. Dermatol. 2000, 115:893-900.
41. Soler C., Allibert P., Chardonnet Y., Cros P., Mandrand B., Thivolet J. Detection of human papillomavirus types 6, 11, 16 and 18 in mucosal and cutaneous lesions by the multiplex polymerase chain reaction. J. Virol. Methods 1991, 35:143-157.
42. Sredoja Tisma V., Basta-Juzbasic A., Jaganjac M., Brcic L., Dobric I., Lipozencic J., Tatzber F., Zarkovic N., Poljak-Blazi M. Oxidative stress and ferritin expression in the skin of rosacea patients. J. Am. Acad. Dermatol. 2009, 60:270-276.
43. Sung H., Kang S.H., Bae Y.J., Hong J.T., Chung Y.B., Lee C.K., Song S. PCR-based detection of Mycoplasma species. J. Microbiol. 2006, 44:42-49.
44. Toyokuni S., Uchida K., Hattori-Nakakuki Y., Hiai H., Stadtman E.R. Formation of 4-hydroxy-2-nonenal - modified proteins in renal proximal tubules of rats treated with renal carcinogen, ferric nitrilotriacetate. Proc. Natl Acad. Sci. USA 1994, 91:2616-2620.
45. Weinberg E.D. Iron withholding: a defense against viral infections. Biometals 1996, 9:393-399.
46. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 18:12-19.
47. Zivkovic M., Poljak-Blazi M., Zarkovic K., Mihaljevic D., Schaur R.J., Zarkovic N. Oxidative burst of neutrophils against melanoma B16-F10. Cancer Lett. 2007, 232:100-108.